Rhythm Pharmaceuticals Reports Topline Data from P-III (TRANSCEND) Trial of Setmelanotide for Acquired Hypothalamic Obesity
Shots:
- The P-III (TRANSCEND) trial (N=120) assessed setmelanotide (n=81: 33 adults & 48 pediatric) vs PBO (n= 39) for acquired hypothalamic obesity in 49 adults & 71 pediatric pts; additional arm of 12 Japanese pts is ongoing, with topline data expected by Q1’26. FDA & EMA filings to be completed by Q3’25
- Trial met its 1EP with a -16.5% vs +3.3% mean BMI change at 52wks., showing -19.2% & -20.2% PBO-adjusted BMI reductions in adult & pediatric pts, respectively. Overall, 80% of treated pts achieved ≥5% BMI reduction
- In 2EPs, 83% of adults & pediatric pts had ≥5% BMI or ≥0.2 BMI Z-score decrease, respectively, while pts (n=81; ≥12yrs.) saw a -1.4 reduction in weekly average daily maximal hunger score vs PBO
Ref: Rhythm Pharmaceuticals | Image: Rhythm Pharmaceuticals
Related News:- Rhythm Pharmaceuticals Reports the US FDA’s Approval of Imcivree (Setmelanotide) for Patients as Young as 2 Years Old
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
